Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach

Patient Preference and Adherence

Volumn 10, Issue , 2016, Pages 2217-2228

  Alten, Rieke ^a   Krüger, Klaus ^b   Rellecke, Julian ^c   Schiffner Rohe, Julia ^d   Behmer, Olaf ^d   Schiffhorst, Guido ^c   Nolting, Hans Dieter ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Praxiszentrum St Bonifatius   (Germany)

^c IGES Institut GmbH   (Germany)

^d PFIZER INC   (United States)

Author keywords

Best worst scaling; Discrete choice experiment; Disease modifying antirheumatic drugs; Patient preferences; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; BOOTSTRAPPING; COMBINATION DRUG THERAPY; DATA ANALYSIS; DECISION MAKING; DISCRETE CHOICE EXPERIMENT; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MIDDLE AGED; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84995695072     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S117774     Document Type: Article

References (45)

1. Lipsky PE. Rheumatoid arthritis. In: Fauci A, Langford C, editors. Harrison’s Rheumatology. New York: McGraw-Hill; 2010:33–42.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285): 903–911.
3. European Musculoskeletal Conditions Surveillance and Information Network. Musculoskeletal Health in Europe: Report v5.0. 2012. Available from: http://www.eumusc.net/myUploadData/files/Musculoskeletal%20Health%20in%20Europe%20Report%20v5.pdf. Accessed November 19, 2015.
4. Silman AJ, Hochberg MC. Descriptive epidemiology of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatoid Arthritis. Amsterdam: Elsevier; 2009: 15–22.
5. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford). 2000;39(Suppl 2):3–12.
6. Deutsche Rheuma-Forschungszentrum. Daten der Kerndokumentation 2013. Available from: http://dgrh.de/fileadmin/media/Forschung/Versorgungsforschung/ErwachsenenKerndok/Standardpraesentation_2013_ extern.pdf. Accessed November 19, 2015.
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013;73(3):492–509.
8. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
9. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 2013;128(5): 309–310.
10. Yazici Y. Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto … let’s call the whole thing off. Arthritis Res Ther. 2012;14(1):104.
11. Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011; 65(4):408–414.
12. Fallowfield L, Atkins L, Catt S, et al. Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17(2):205–210.
13. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med. 2001;23(2):125–132.
14. Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients’ problems with new medication for chronic conditions. Qual Saf Health Care. 2004; 3(3):172–175.
15. Glombiewski JA, Nestoriuc Y, Rief W, Glaesmer H, Braehler E. Medication adherence in the general population. PLoS One. 2012;7(12): e50537.
16. Pasma A, van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013; 43(1):18–28.
17. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337–351.
18. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–344.
19. Chilton F, Collett RA. Treatment choices, preferences and decisionmaking by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6(1):1–14.
20. Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology (Oxford). 2002;41(3):253–261.
21. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Patient preferences for treatment: report from a randomized comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007;66(9):1227–1232.
22. Lempp H, Hofmann D, Hatch SL, Scott DL. Patients’ views about treatment with combination therapy for rheumatoid arthritis: a comparative qualitative study. BMC Musculoskelet Disord. 2012;13:200.
23. Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis: results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010;49(2):289–294.
24. Willeke P, Becker H, Wassenberg S, Pavenstädt H, Jacobi AM. Bewertung einer Infusionbehandlung der rheumatoiden Arthritis durch Patienten und Rheumatologen [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis]. Z Rheumatol. 2011;70(3):232–234, 236–238. German.
25. Flynn TN, Louviere JJ, Peters TJ, Coast J. Best-worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007; 26(1):171–189.
26. Potoglou D, Burge P, Flynn T, et al. Best-worst scaling vs. discrete choice experiments: an empirical comparison using social care data. Soc Sci Med. 2011;72(10):1717–1727.
27. Marley AA, Louviere JJ. Some probabilistic models of best, worst, and best-worst choices. J Math Psychol. 2005;49:464–480.
28. Deutsche Gesellschaft für Rheumatologie. Berlin: Rheuma in Zahlen: Betroffene Menschen in Deutschland. 2008. Available from: http://dgrh.de/fileadmin/media/Die_DGRH/Presse/Rheuma_in_Zahlen_presse_ aktual.pdf. Accessed November 19, 2015.
29. Federov V. Theory of Optimal Experiments. New York: Academic Press; 1972.
30. Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3–13.
31. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Patientcentered rheumatoid arthritis disease activity assessment by a modified RADAI. J Rheumatol. 2008;35(7):1294–1299.
32. Rintelen B, Haindl PM, Sautner J, Leeb BA, Deutsch C, Leeb BF. The rheumatoid arthritis disease activity index-5 in daily use: proposal for disease activity categories. J Rheumatol. 2009;36(5):918–924.
33. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing cognitive representations of medication. Psychol Health. 1999;14(1):1–24.
34. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–567.
35. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford). 2005;44(6):762–767.
36. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012; 64(5):640–647.
37. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity-concerns framework. J Psychosom Res. 2008; 64(1):41–46.
38. Finn A, Louviere JJ. Determining the appropriate response to evidence of public concern: the case of food safety. J Public Policy Mark. 1992; 11(2):12–25.
39. Auger P, Deevinney TM, Louviere J. Using best-worst scaling methodology to investigate ethical beliefs across countries. J Bus Ethics. 2007;70:299–326.
40. Flynn TN, Louviere JJ, Peters TJ, Coast J. Estimating preferences for a dermatology consultation using best-worst scaling: comparison of various methods of analysis. BMC Med Res Methodol. 2008;8:76.
41. Gesundheitsberichterstattung des Bundes. Das Informations system der Gesundheitsberichterstattung des Bundes. 2014. Available from: http:// www.gbe-bund.de. Accessed November 19, 2015.
42. Skjoldborg US, Lauridsen J, Junker P. Reliability of the discrete choice experiment at the input and output level in patients with rheumatoid arthritis. Value Health. 2009;12(1):153–158.
43. Augustovski F, Beratarrechea A, Irazola V, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health. 2013;16(2):385–393.
44. Poulos C, Hauber AB, González JM, Turpcu A. Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken). 2014;66(7):1008–1015.
45. Louder AM, Singh A, Saverno K, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits. 2016;9(2):84–93.